Huntington Disease Treated with Austedo (Deutetrabenazine)

Huntington's disease (HD) is a neurodegenerative disorder characterized by chorea, cognitive decline, and psychiatric symptoms. Austedo (deutetrabenazine) represents a significant advancement in the treatment of chorea associated with HD, being the first deuterated drug approved by the US Food and Drug Administration (FDA) for this purpose. Deutetrabenazine, a modified form of tetrabenazine, acts by inhibiting vesicular monoamine transporter 2 (VMAT2), thereby reducing dopamine levels. Its unique structure, incorporating deuterium instead of hydrogen, prolongs its half-life and allows for less frequent dosing. Clinical trials, such as Phase III First HD, have demonstrated deutetrabenazine's efficacy in improving chorea symptoms in HD patients, with favorable tolerability reported. Despite similarities in effectiveness with tetrabenazine, deutetrabenazine offers a potentially better-tolerated option for chorea treatment in HD. However, further research, including direct comparative studies and long-term data, is necessary to fully elucidate its advantages over existing therapies.